Parasite-mediated upregulation of NK cell-derived gamma interferon protects against severe highly pathogenic H5N1 influenza virus infection

Journal of Virology

Volumn 85, Issue 17, 2011, Pages 8680-8688

  O'Brien, Kevin B ^a,b   Schultz Cherry, Stacey ^a   Knoll, Laura J ^b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; PARASITE ANTIGEN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; INFLUENZA A (H5N1); INTERFERON PRODUCTION; LUNG; LYMPHOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TH1 CELL; TOXOPLASMA GONDII; UPREGULATION; VIRAL CLEARANCE; VIRUS TITRATION; VIRUS VIRULENCE;

ANIMALS; ANTIGENS, PROTOZOAN; DISEASE MODELS, ANIMAL; INFLUENZA A VIRUS, H5N1 SUBTYPE; INTERFERON-GAMMA; KILLER CELLS, NATURAL; LUNG; MICE; MICE, INBRED C57BL; ORTHOMYXOVIRIDAE INFECTIONS; SURVIVAL ANALYSIS; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; VIRAL LOAD;

AVES; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE; TOXOPLASMA GONDII;

EID: 80052275302     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05142-11     Document Type: Article

References (52)

1. Baumgarth, N., and A. Kelso. 1996. Functionally distinct T cells in three compartments of the respiratory tract after influenza virus infection. Eur. J. Immunol. 26:2189-2197.
2. Brunelle, M. N., et al. 2010. Inhibition of hepatitis B virus DNA replication by a thermostable interferon-gamma variant. Antivir. Ther. 15:861-869.
3. Capua, I., and G. Cattoli. 2009. Flu: vaccinate to cut risk of chimaeric virus emerging. Nature 460:571.
4. Carlson, C. M., et al. 2010. Transforming growth factor-beta: activation by neuraminidase and role in highly pathogenic H5N1 influenza pathogenesis. PLoS Pathog. 6:e1001136.
5. Craver, M. P., P. J. Rooney, and L. J. Knoll. 2010. Isolation of Toxoplasma gondii development mutants identifies a potential proteophosphoglycan that enhances cyst wall formation. Mol. Biochem. Parasitol. 169:120-123.
6. Denkers, E. Y. 2003. From cells to signaling cascades: manipulation of innate immunity by Toxoplasma gondii. FEMS Immunol. Med. Microbiol. 39:193-203.
7. Denkers, E. Y., R. T. Gazzinelli, S. Hieny, P. Caspar, and A. Sher. 1993. Bone marrow macrophages process exogenous Toxoplasma gondii polypeptides for recognition by parasite-specific cytolytic T lymphocytes. J. Immunol. 150:517-526.
8. Denkers, E. Y., R. T. Gazzinelli, D. Martin, and A. Sher. 1993. Emergence of NK1.1+ cells as effectors of IFN-gamma dependent immunity to Toxoplasma gondii in MHC class I-deficient mice. J. Exp. Med. 178:1465-1472.
9. Dubey, J. P. 1998. Advances in the life cycle of Toxoplasma gondii. Int. J. Parasitol. 28:1019-1024.
10. Ehrhardt, C., and S. Ludwig. 2009. A new player in a deadly game: influenza viruses and the PI3K/Akt signalling pathway. Cell. Microbiol. 11:863-871.
11. Flores, M., et al. 2008. Macrophage migration inhibitory factor (MIF) is critical for the host resistance against Toxoplasma gondii. FASEB J. 22:3661-3671.
12. Frankel, M. B., D. G. Mordue, and L. J. Knoll. 2007. Discovery of parasite virulence genes reveals a unique regulator of chromosome condensation 1 ortholog critical for efficient nuclear trafficking. Proc. Natl. Acad. Sci. U. S. A. 104:10181-10186.
13. Gazzinelli, R. T., E. Y. Denkers, and A. Sher. 1993. Host resistance to Toxoplasma gondii: model for studying the selective induction of cell-mediated immunity by intracellular parasites. Infect. Agents Dis. 2:139-149.
14. Gentry, L. O., and J. S. Remington. 1971. Resistance against Cryptococcus conferred by intracellular bacteria and protozoa. J. Infect. Dis. 123:22-31.
15. Ghedin, E., et al. 2009. Mixed infection and the genesis of influenza virus diversity. J. Virol. 83:8832-8841.
16. Girard, M. P., J. S. Tam, O. M. Assossou, and M. P. Kieny. 2010. The 2009 A (H1N1) influenza virus pandemic: a review. Vaccine 28:4895-4902.
17. Golding, H., et al. 2003. Inhibition of HIV-1 infection by a CCR5-binding cyclophilin from Toxoplasma gondii. Blood 102:3280-3286.
18. Graham, M. B., et al. 1993. Response to influenza infection in mice with a targeted disruption in the interferon gamma gene. J. Exp. Med. 178:1725-1732.
19. Hayden, F. 2009. Developing new antiviral agents for influenza treatment: what does the future hold? Clin. Infect. Dis. 48(Suppl. 1):S3-S13.
20. Huang, S., et al. 1993. Immune response in mice that lack the interferongamma receptor. Science 259:1742-1745.
21. Ilyinskii, P. O., G. Thoidis, and A. M. Shneider. 2008. Development of a vaccine against pandemic influenza viruses: current status and perspectives. Int. Rev. Immunol. 27:392-426.
22. Jones, J. C., E. A. Turpin, H. Bultmann, C. R. Brandt, and S. Schultz-Cherry. 2006. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J. Virol. 80:11960-11967.
23. Khoufache, K., et al. 2009. Protective role for protease-activated receptor-2 against influenza virus pathogenesis via an IFN-γ-dependent pathway. J. Immunol. 182:7795-7802.
24. Ludwig, S., and O. Planz. 2008. Influenza viruses and the NF-kappaB signaling pathway-towards a novel concept of antiviral therapy. Biol. Chem. 389:1307-1312.
25. Mahmoud, A. A., K. S. Warren, and G. T. Strickland. 1976. Acquired resistance to infection with Schistosoma mansoni induced by Toxoplasma gondii. Nature 263:56-57.
26. Mason, N. J., H. C. Liou, and C. A. Hunter. 2004. T cell-intrinsic expression of c-Rel regulates Th1 cell responses essential for resistance to Toxoplasma gondii. J. Immunol. 172:3704-3711.
27. Mordue, D. G., C. F. Scott-Weathers, C. M. Tobin, and L. J. Knoll. 2007. A patatin-like protein protects Toxoplasma gondii from degradation in activated macrophages. Mol. Microbiol. 63:482-496.
28. Morrow, A. N., H. Schmeisser, T. Tsuno, and K. C. Zoon. 2011. A novel role for IFN-stimulated gene factor 3II in IFN-γ signaling and induction of antiviral activity in human cells. J. Immunol. 186:1685-1693.
29. Morton, D. B. 2000. A systematic approach for establishing humane end-points. ILAR J. 41:80-86.
30. Murray, H. W. 1996. Current and future clinical applications of interferongamma in host antimicrobial defense. Intensive Care Med. 22(Suppl. 4): S456-S461.
31. Pleschka, S. 2008. RNA viruses and the mitogenic Raf/MEK/ERK signal transduction cascade. Biol. Chem. 389:1273-1282.
32. Poland, G. A., R. M. Jacobson, and I. G. Ovsyannikova. 2009. Influenza virus resistance to antiviral agents: a plea for rational use. Clin. Infect. Dis. 48:1254-1256.
33. Price, G. E., A. Gaszewska-Mastarlarz, and D. Moskophidis. 2000. The role of alpha/beta and gamma interferons in development of immunity to influenza A virus in mice. J. Virol. 74:3996-4003.
34. Pulendran, B. 2004. Modulating TH1/TH2 responses with microbes, dendritic cells, and pathogen recognition receptors. Immunol. Res. 29:187-196.
35. Remington, J. S., and T. C. Merigan. 1969. Resistance to virus challenge in mice infected with protozoa or bacteria. Proc. Soc. Exp. Biol. Med. 131:1184-1188.
36. Richmond, J. Y., and R. W. McKinney III (ed.). 1993. Biosafety in microbiological and biomedical laboratories. U.S. Department of Health and Human Services, Washington, DC, and Centers for Disease Control, Atlanta, GA.
37. Ruf, B. R., and T. Szucs. 2009. Reducing the burden of influenza-associated complications with antiviral therapy. Infection 37:186-196.
38. Ruskin, J., and J. S. Remington. 1968. Immunity and intracellular infection: resistance to bacteria in mice infected with a protozoan. Science 160:72-74.
39. Sassi, A., et al. 2009. Toxoplasma gondii inhibits R5 HIV-1 replication in human lymphoid tissues ex vivo. Microbes Infect. 11:1106-1113.
40. Scharton-Kersten, T. M., et al. 1996. In the absence of endogenous IFN-gamma, mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection. J. Immunol. 157:4045-4054.
41. Schneider, D. S., and J. S. Ayres. 2008. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. Nat. Rev. Immunol. 8:889-895.
42. Schnitzler, S. U., and P. Schnitzler. 2009. An update on swine-origin influenza virus A/H1N1: a review. Virus Genes 39:279-292.
43. Strehl, B., et al. 2005. Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol. Rev. 207:19-30.
44. Suzuki, Y., M. A. Orellana, R. D. Schreiber, and J. S. Remington. 1988. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 240:516-518.
45. Tassi, I., J. Klesney-Tait, and M. Colonna. 2006. Dissecting natural killer cell activation pathways through analysis of genetic mutations in human and mouse. Immunol. Rev. 214:92-105.
46. Tumpey, T. M., X. Lu, T. Morken, S. R. Zaki, and J. M. Katz. 2000. Depletion of lymphocytes and diminished cytokine production in mice infected with a highly virulent influenza A (H5N1) virus isolated from humans. J. Virol. 74:6105-6116.
47. Walzer, T., et al. 2007. Identification, activation, and selective in vivo ablation of mouse NK cells via NKp46. Proc. Natl. Acad. Sci. U. S. A. 104:3384-3389.
48. Weiss, I. D., et al. 2010. IFN-gamma treatment at early stages of influenza virus infection protects mice from death in a NK cell-dependent manner. J. Interferon Cytokine Res. 30:439-449.
49. Wiley, J. A., A. Cerwenka, J. R. Harkema, R. W. Dutton, and A. G. Harmsen. 2001. Production of interferon-gamma by influenza hemagglutinin-specific CD8 effector T cells influences the development of pulmonary immunopathology. Am. J. Pathol. 158:119-130.
50. Wohlleben, G., and K. J. Erb. 2004. The absence of IFN-gamma leads to increased Th2 responses after influenza A virus infection characterized by an increase in CD4+ but not CD8+ T cells producing IL-4 or IL-5 in the lung. Immunol. Lett. 95:161-166.
51. Writing Committee of the WHO Consultation on Clinical Aspects of Pandemic (H1N1) 2009 Influenza. 2010. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N. Engl. J. Med. 362:1708-1719.
52. Yen, H. L., and R. G. Webster. 2009. Pandemic influenza as a current threat. Curr. Top. Microbiol. Immunosl. 333:3-24.